Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …

Biotechnology

US, Newark [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Rain Therapeutics Inc.'s gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

Rain Therapeutics Inc. can't present any analysts estimates at the moment detail analysis.